Skip to main content
Caplight Logo









Primary Peptides, Inc.

Primary Peptides, Inc.

Private
VancouverHealthcare & Life Scienceshttps://primarypeptides.com/

Last Round

Series A

Feb 1, 2025

Est. Valuation

$75M

Total Funding Raised

$229,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Primary Peptides, Inc. is a biotechnology company that develops novel peptide therapeutics for neurological and cardiovascular diseases using protein manipulation technologies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

peptide therapeuticsbiotech platformneurodegenerative diseasedrug discoveryCNS therapeuticsblood-brain barrierprotein degradationCHAPTACundruggable targetsbiotech licensingprotein-protein interactiondrug pipelinetargeted therapynext-gen biologicsprotein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Primary Peptides, Inc. Comparables

Compare Primary Peptides, Inc. with similar companies based on industry and business-model similarity.

Primary Peptides, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Argenica Therapeutics
83%
Axoltis Pharma
82%
Infensa Bioscience
79%

Primary Peptides, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 1, 2025
GrantMay 1, 2023
GrantMay 2, 2022

Primary Peptides, Inc. Investors

Notable investors and investment history

Primary Peptides, Inc. investors
InvestorRounds
National Research Council of CanadaGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 413% MoM.

  • May 15, 2026

    Monthly visitors increased 435% MoM.

Primary Peptides, Inc. Filings

Explore SEC and related filing metadata, where available.

Primary Peptides, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Primary Peptides, Inc.'s valuation, stock price, and market status.

Is Primary Peptides, Inc. a public or private company?

Primary Peptides, Inc. is a private company.

What is the current stock price of Primary Peptides, Inc.?

Primary Peptides, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Primary Peptides, Inc. worth (valuation)?

Primary Peptides, Inc.'s valuation is estimated at $75.0M based on funding round data.

Can I buy Primary Peptides, Inc. stock?

Primary Peptides, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Primary Peptides, Inc.'s last funding round?

Primary Peptides, Inc.'s most recent funding round was Series A on February 1, 2025.

Who are the main investors in Primary Peptides, Inc.?

Key investors in Primary Peptides, Inc. include National Research Council of Canada.

Will Primary Peptides, Inc. IPO soon?

No public IPO plans have been announced for Primary Peptides, Inc..

How can I track Primary Peptides, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Primary Peptides, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersVancouver
Employee Range4
Year Founded2013
Last FundingFeb 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?